表紙
市場調查報告書

青光眼治療藥的全球市場:各類藥物,各適應症,各流通管道,各地區的趨勢分析,市場佔有率,預測:2016年-2026年

Glaucoma Therapeutics Market, By Drug Class, By Disease Indication, By Distribution Channel, By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26

出版商 Blueweave Consulting & Research Private Limited 商品編碼 948272
出版日期 內容資訊 英文 180 Pages
商品交期: 最快1-2個工作天內
價格
青光眼治療藥的全球市場:各類藥物,各適應症,各流通管道,各地區的趨勢分析,市場佔有率,預測:2016年-2026年 Glaucoma Therapeutics Market, By Drug Class, By Disease Indication, By Distribution Channel, By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26
出版日期: 2020年03月01日內容資訊: 英文 180 Pages
簡介

全球青光眼治療市場,預計從2019年的62億7,000萬美元到2026年達76億5,000萬美元,從2020年到2026年的年複合成長率預計為2.96%。近幾年青光眼的早期發現和治療的重要性廣泛受到認識,也進行診斷工具的改良,青光眼治療藥的市場踏實擴大。

本報告提供全球青光眼治療藥市場調查,彙整產業的考察,市場概要,各地區市場分析,主要企業的簡介等資訊。

目錄

第1章 調查架構

第2章 調查手法

第3章 摘要整理

第4章 產業的考察

  • DROC分析
    • 成長促進因素
    • 成長阻礙因素
    • 市場機會
    • 課題
  • 技術方面情勢
  • 法律規範
  • 各公司的市場佔有率分析
  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 新加入廠商勢力的威脅
    • 替代品的威脅
    • 企業間的競爭

第5章 全球市場概要

  • 市場規模與預測:2016-2026
  • 市場佔有率與預測:2016-2026
    • 各適應症
      • 開放角落角綠內症
      • 隅角閉鎖性青光眼
      • 其他
    • 各類藥物
      • 乙型阻斷劑
      • 前列腺素類似體
      • α腎上腺素受體激動劑
      • 碳酸酐酵素抑制劑
      • 並用藥
      • 其他
    • 各流通管道
      • 醫院藥局
      • 零售藥局
      • 線上藥局
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第6章 北美市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測:2016-2026
  • 各適應症
  • 各類藥物
  • 各流通管道
  • 各國
    • 美國
    • 加拿大

第7章 歐洲市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測:2016-2026
  • 各適應症
  • 各類藥物
  • 各流通管道
  • 各國
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他

第8章 亞太地區市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測:2016-2026
  • 各適應症
  • 各類藥物
  • 各流通管道
  • 各國
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他

第9章 南美市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測:2016-2026
  • 各適應症
  • 各類藥物
  • 各流通管道
  • 各國
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他

第10章 中東、非洲市場

  • 市場規模與預測:2016∼2026
  • 市場佔有率與預測:2016-2026
  • 各適應症
  • 各類藥物
  • 各流通管道
  • 各國
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 其他

第11章 企業簡介 (公司概要,財務矩陣,流程概況,主要人物,主要的競爭企業,聯絡原住所,策略性展望)*

  • The Linde Group
  • Air Liquide S.A.
  • Illinois Tool Works Inc.
  • Colfax Corporation
  • Lincoln Electric Holdings Inc.
  • Messer Group
  • African Oxygen Limited
  • GCE Holding AB
  • Koike Aronson, Inc.
  • Fronius International GmbH
  • Matheson Tri-Gas, Inc.
  • Bug-O Systems Inc.
  • Gentec (Shanghai) Corporation
  • British Oxygen Company
  • Muller Opladen
  • Cavagna Group
  • Rotarex
  • Other Prominent Players
目錄
Product Code: BWC19434

Title:
Therapeutics Market, By Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Combination Drugs), By Disease Indication (Open Angle Glaucoma, Angle Closure Glaucoma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26.

According to BlueWeave Consulting, the Global Glaucoma Therapeutics market has reached USD 6.27 Billion in 2019 and estimated to reach USD 7.65 Billion in 2026, at a CAGR of 2.96% during the forecast period 2020-2026. Glaucoma prevalence is oriented towards the geriatric population, and the rising geriatric population globally is likely to have a positive impact on the global market.

Glaucoma has affected about 64 million people worldwide. Glaucoma is a condition that can affect the optic nerve, and any level of glaucoma can result in partial or complete blindness. The severity of glaucoma has led to increased awareness among end-users of ways to manage glaucoma, and people realized the importance of early detection and treatment of this disease. Besides, improved diagnostic tools for glaucoma diagnosis are likely to favor the development of the global Glaucoma Therapeutics Market in the years ahead. These are high glaucoma prevalence, enhanced technical support during diagnosis, and increased awareness of glaucoma-related care. Such factors will push the global market for glaucoma therapy to the forefront. With the introduction of pipeline products during the forecast period for the launch of late-stage products into the glaucoma market. The drugs include the DE-117 drug from Santen and another with unspecified MOA, Roclatan fixed-dose combination therapy from Aerie, and two Sustained-release (SR) implants.

Transforming lifestyle is one of the key factors for driving global Glaucoma Therapeutics market in upcoming years

Changing a lifestyle where people spend a lot of time in front of a smart gadget which emits blue ray. This introduction now begins at a very early age. It is also common in older generations who are more vulnerable to such diseases than younger-age individuals. The rise in the geriatric population can also be seen to determine the future direction for the glaucoma therapy market. There are also various treatments available to counter the problem. One such is the relatively inexpensive and precise laser treatment. In addition, increasing patient awareness of glaucoma and the introduction of favorable reimbursement policies are some of the main factors predicted to boost the growth of the glaucoma therapy market in North America in the coming years.

Prostaglandin Analogues to be the Most Widely Used In Drug Class

Prostaglandin Analogues hold the highest market share in the year 2026. Prostaglandins have changed the face of the care scenario for glaucoma and are used as first-line glaucoma therapy. The segment of prostaglandin analogs represented a significant market share in 2019 and is expected to remain dominant throughout the 2020-2026 forecast period. Besides, the increasing adoption of prostaglandin analogs is likely to favor the growth of the global therapeutic market for glaucoma. Key factors such as government initiatives and population health awareness programs will drive market growth, and postoperative complications that occur after glaucoma surgery will catalyze the global glaucoma therapy market.

North America expected to witness significant growth in the market in the upcoming years

Due to the large health-care system, North America is expected to dominate the glaucoma therapy market. Followed by North America, Europe & Asia-Pacific will lead in the coming years to significant growth in the global glaucoma market. Consistent Increase in Glaucoma Prevalence Rising market growth with the highest rate in the Asia Pacific. The North American region's superiority is due to the US's effective care system for severe ophthalmological disorders, and the provision of well-equipped medical facilities for glaucoma diagnosis. Asia Pacific is expected to see relatively significant CAGR in 2019-2026 due to the increasing number of cases diagnosed with glaucoma in countries such as China and India and efforts being made by public authorities in those countries to prevent and monitor glaucoma. The increasing geriatric population in Japan also contributes to the Asia-Pacific glaucoma therapy market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary Research Respondents
  • 2.5. Market Size Estimation
  • 2.6. Assumption for The Study
  • 2.7. Market Breakdown & Data Triangulation

3. Executive Summary

4. Global Glaucoma Therapeutics Insights

  • 4.1. DROC Analysis
    • 4.1.1. Growth Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. Technological Landscape
  • 4.3. Regulatory Framework
  • 4.4. Company Market Share Analysis, 2019
  • 4.5. Porter's Five forces analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Intensity of Rivalry

5. Global Glaucoma Therapeutics Market Overview

  • 5.1. Market Size & Forecast by Value, 2016-2026
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast 2016-2026
    • 5.2.1. By Disease Indication
      • 5.2.1.1. Open-Angle Glaucoma
      • 5.2.1.2. Angle Closure Glaucoma
      • 5.2.1.3. Others
    • 5.2.2. By Drug Class
      • 5.2.2.1. Beta-Blockers
      • 5.2.2.2. Prostaglandin Analogues
      • 5.2.2.3. Alpha Adrenergic Agonists
      • 5.2.2.4. Carbonic Anhydrase Inhibitors
      • 5.2.2.5. Combination Drugs
      • 5.2.2.6. Others
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospital Pharmacy
      • 5.2.3.2. Retail Pharmacy
      • 5.2.3.3. Online Pharmacy
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia Pacific
      • 5.2.4.4. Latin America
      • 5.2.4.5. Middle East & Africa

6. North America Glaucoma Therapeutics Market

  • 6.1. Market Size & Forecast by Value, 2016-2026
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast 2016-2026
    • 6.2.1. By Disease Indication
    • 6.2.2. By Drug Class
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
      • 6.2.4.1. U.S
      • 6.2.4.2. Canada

7. Europe Glaucoma Therapeutics Market

  • 7.1. Market Size & Forecast by Value, 2016-2026
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast 2016-2026
    • 7.2.1. By Disease Indication
    • 7.2.2. By Drug Class
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. Germany
      • 7.2.4.2. U.K
      • 7.2.4.3. France
      • 7.2.4.4. Italy
      • 7.2.4.5. Spain
      • 7.2.4.6. Rest of Europe

8. Asia Pacific Glaucoma Therapeutics Market

  • 8.1. Market Size & Forecast by Value, 2016-2026
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast 2016-2026
    • 8.2.1. By Disease Indication
    • 8.2.2. By Drug Class
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. China
      • 8.2.4.2. India
      • 8.2.4.3. Japan
      • 8.2.4.4. South Korea
      • 8.2.4.5. Rest of Asia Pacific

9. Latin America Glaucoma Therapeutics Market

  • 9.1. Market Size & Forecast by Value, 2016-2026
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast 2016-2026
    • 9.2.1. By Disease Indication
    • 9.2.2. By Drug Class
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Brazil
      • 9.2.4.2. Mexico
      • 9.2.4.3. Argentina
      • 9.2.4.4. Rest of Latin America

10.Middle East & Africa Glaucoma Therapeutics Market

  • 10.1. Market Size & Forecast by Value, 2016-2026
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast 2016-2026
    • 10.2.1. By Disease Indication
    • 10.2.2. By Drug Class
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. Saudi Arabia
      • 10.2.4.2. UAE
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of Middle East & Africa

11.Company Profile (Company Overview, Financial Matrix, Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 11.1. The Linde Group
  • 11.2. Air Liquide S.A.
  • 11.3. Illinois Tool Works Inc.
  • 11.4. Colfax Corporation
  • 11.5. Lincoln Electric Holdings Inc.
  • 11.6. Messer Group
  • 11.7. African Oxygen Limited
  • 11.8. GCE Holding AB
  • 11.9. Koike Aronson, Inc.
  • 11.10. Fronius International GmbH
  • 11.11. Matheson Tri-Gas, Inc.
  • 11.12. Bug-O Systems Inc.
  • 11.13. Gentec (Shanghai) Corporation
  • 11.14. British Oxygen Company
  • 11.15. Muller Opladen
  • 11.16. Cavagna Group
  • 11.17. Rotarex
  • 11.18. Other Prominent Players

List of Figures:

Fig: Global Glaucoma Therapeutics Segmentation

Fig: Company Market Share Analysis, 2019

Fig: Global Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Global Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Global Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Global Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Global Glaucoma Therapeutics Market Share, By Region, By Value, 2016-2026

Fig: North America Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: North America Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: North America Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: North America Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: North America Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: North America Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

Fig: Europe Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Europe Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: Europe Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Europe Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Europe Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Europe Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: Latin America Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

Fig: Middle-East & Africa Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Middle-East & Africa Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: Middle East & Africa Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Middle East & Africa Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Middle East & Africa Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Middle East & Africa Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

List of Tables:

Table: Global Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Global Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Global Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Global Glaucoma Therapeutics Market Size, By Region, By Value, 2016-2026

Table: North America Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: North America Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: North America Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: North America Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Europe Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Europe Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Europe Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Europe Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Asia-Pacific Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Asia-Pacific Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Asia-Pacific Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Asia-Pacific Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Latin America Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Latin America Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Latin America Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Latin America Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Middle East & Africa Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Middle East & Africa Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Middle East & Africa Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Middle East & Africa Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Merck & Co., Inc. Financial Analysis

Table: Novartis AGFinancial Analysis

Table: Allergan plc Financial Analysis

Table: Bausch & Lomb IncorporatedFinancial Analysis

Table: Teva Pharmaceutical IndustryFinancial Analysis

Table: Aerie PharmaceuticalFinancial Analysis

Table: Pfizer Inc.Financial Analysis

Table: Inotek PharmaceuticalsFinancial Analysis